SCHEDULE 13G/A: Stonepine Capital Discloses 6.0% Stake in TELA Bio, Inc.
Beneficial Ownership Disclosure
Stonepine Capital Management, LLC and its affiliates have disclosed a 6.0% beneficial ownership stake in TELA Bio, Inc. as of December 31, 2024.
Summary
- Stonepine Capital Management, LLC, Stonepine Capital, L.P., Stonepine GP, LLC, and Jon M. Plexico (collectively, the 'Reporting Persons') have filed an Amendment No. 1 to Schedule 13G.
- The filing indicates that the Reporting Persons collectively beneficially own 2,353,099 shares of Common Stock of TELA Bio, Inc.
- This ownership represents 6.0% of TELA Bio, Inc.'s outstanding Common Stock.
- The percentage is calculated based on 39,388,443 shares of Common Stock outstanding as of November 1, 2024, as reported in TELA Bio, Inc.'s Form 10-Q for the quarter ended September 30, 2024.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a standard beneficial ownership disclosure (Schedule 13G) and does not contain information that would inherently suggest a positive or negative sentiment regarding the issuer's performance or outlook. It is a factual report of an investment stake.
Future Outlook
NA
Industry Context
This filing indicates an institutional investment firm, Stonepine Capital, has taken a significant passive stake in TELA Bio, Inc., a company operating in the healthcare or medical device sector. Such disclosures are common and reflect investment decisions by funds based on their analysis of the company's prospects within its industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake may be viewed positively by other investors as a vote of confidence in the company, potentially influencing stock price.
Key Dates
| Date | Description |
|---|---|
| 2024-10-10 | Date of Agreement Regarding Joint Filing of Statement on Schedule 13D or 13G. |
| 2024-11-01 | Date as of which 39,388,443 shares of Common Stock were outstanding, as reported in the Issuer's Form 10-Q. |
| 2024-12-31 | Date of event which requires filing of this statement (reporting period end date for beneficial ownership). |
| 2025-02-13 | Signature date of the Schedule 13G filing. |
Keywords
TELA Bio Inc., Stonepine Capital Management, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Institutional Investment, Equity Stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.